Evolent Health vs ICF International
EVH and ICFI side by side, both in management and public relations services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVH and ICFI compare
ICF International is the larger company, worth 2.6 times as much as Evolent Health ($1.4B against $546M).
Evolent Health grew revenue faster over the last twelve months (−4.5% versus −7.9% for ICF International).
ICF International keeps more of each dollar of sales as profit, with a net margin of 4.9% compared with −24.1% at Evolent Health.
ICF International pays a dividend yielding 0.71%; Evolent Health does not pay one.
ICF International scores higher on the StockData Score (20 against 7 for Evolent Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVH | ICFI |
|---|---|---|
| Size and price | ||
| Market cap | $546M | $1.4B |
| Share price | $4.83 | $79.42 |
| Change, 1 year | 16.1% | 0.23% |
| Change, 5 years | −81.6% | −20.8% |
| Beta (5Y) | 1.91 | 1.41 |
| Employees | 4,200 | 8,400 |
| StockData Score | ||
| Total score | 7 | 20 (better) |
| Valuation score | 3 | 6 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 0 | 4 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | – | 16.4× |
| P/S | 0.3× (better) | 0.8× |
| P/B | 1.4× | 1.4× (better) |
| EV/EBITDA | – | 9.3× |
| P/FCF | – | 7.2× |
| PEG | – | 1.21 |
| FCF yield | – | 13.9% |
| Fair value | $10.40 | $119.66 |
| Margin of safety | 53.5% (better) | 33.6% |
| Growth | ||
| Revenue growth (TTM) | −4.5% (better) | −7.9% |
| Revenue growth, 5Y average | 15.2% (better) | 4.4% |
| Net income growth (TTM) | – | −17.8% |
| EPS growth (TTM) | – | −16.0% |
| EPS growth, 5Y average | – | 11.5% |
| Profitability | ||
| Gross margin | 17.2% | 37.2% (better) |
| Operating margin | −20.4% | 7.8% (better) |
| Net margin | −24.1% | 4.9% (better) |
| FCF margin | – | 10.9% |
| Return on equity | −79.0% | 8.6% (better) |
| Return on invested capital | −24.1% | 7.7% (better) |
| Financial health | ||
| Debt / equity | 2.52 | 0.39 (better) |
| Net debt / EBITDA | – | 2.05 |
| Interest coverage | −6.2× | 4.9× (better) |
| Current ratio | 1.24 | 1.39 (better) |
| Altman Z-score | −0.35 | 2.66 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.71% |
| Payout ratio | – | 11.6% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Buyback yield | – | 3.2% |
| Shareholder yield | 0.00% | 3.9% (better) |
| Ownership | ||
| Held by institutions | 99.3% | 102% |
| Held by insiders | 3.3% | 1.8% |
| Insider net buying, 12 months | −$329K (better) | −$1.4M |
| Short interest, % of float | 9.7% | 3.6% |
Go deeper
- EVH stock overview
- EVH income statement
- EVH valuation and score
- ICFI stock overview
- ICFI income statement
- ICFI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.